Fixed combination perindopril-amlodipine – optimised treatment in hypertension and coronary artery disease.

Arterijska hipertenzija (AH) predstavlja najveći pojedinačni čimbenik rizika koji doprinosi globalnoj smrtnosti. Usprkos stalnom poboljšanju liječenja, samo jedna trećina liječenih bolesnika ima dostignite željene vrijednosti arterijskog tlaka (AT). Novija klinička istraživanja navode da pristup korištenja monoterapije za kontrolu AH vjerojatno neće biti uspješan kod mnogih bolesnika. Stoga prednost ima kombinirana terapija, temeljem činjenice da AH doprinose višestruki čimbenici, a postizanje kontrole AT sa samo jednim lijekom koje djeluje preko jednog mehanizma vjerojatno neće biti dostatno. Kombiniranjem lijekova u odgovarajućoj dozi smanjuje se doza pojedinačnih komponenti i učestalost nuspojava te se poboljšava suradljivost bolesnika. Temeljem dokaza iz studije Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure-Lowering Arm kombinacija inhibitora angiotenzin konvertirajućeg enzima (ACE) i blokatora kalcijevih kanala (CCB) predstavlja liječenje izbora kod AH. Kombinacija perindoprila i amlodipina jedini je oblik liječenja kombinacijom ACE inhibitora i CCB koje je dokazalo da zadovoljava primarni cilj antihipertenzivne terapije, tj. cjelokupnom smanjenju pobola i smrti povezanog s AH. Krka je trenutno jedina generička tvrtka koja nudi fiksnu kombinaciju perindoprila i amlodipina i tako omogućava učinkovito liječenje prilagođeno pojedinačnim potrebama bolesnika i liječnika.Hypertension is currently the biggest single risk factor contributing to global death. Despite the constantly improving treatments, only one third of patients who are treated have a normalisation of blood pressure (BP). Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy is preferred, based on the fact that multiple factors contribute to hypertension and achieving control of BP with a single agent acting through one particular mechanism may not be possible. Combining the medicines makes them available in a convenient dosing format and lowers the dose of individual components, thus reducing the side effects and improving compliance. Based on evidence from the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure-Lowering Arm (ASCOT-BPLA), the combination of an angiotensin-converting enzyme (ACE) inhibitor with a calcium channel blocker (CCB) is one of the preferred therapeutic options. The combination perindopril-amlodipine is the only treatment among ACE inhibitor and CCB combinations that has been demonstrated to meet the primary objective of antihypertensive therapy, that is, overall reduction of hypertension-related death and morbidity. Krka is now the only generic company offering a fixed combination of perindopril and amlodipine and thus enabling effective treatment tailored to the individual needs of patients and physicians